688276 百克生物
已收盘 04-24 15:00:00
资讯
新帖
简况
百克生物寒冬已至:营收降五成、净利暴跌213% 核心产品量价齐跌
新浪证券 · 04-24 16:00
百克生物寒冬已至:营收降五成、净利暴跌213% 核心产品量价齐跌
【私募调研记录】瞰道资产调研百克生物
证券之星 · 04-24 08:02
【私募调研记录】瞰道资产调研百克生物
股市必读:百克生物(688276)4月23日披露最新机构调研信息
证券之星 · 04-24 04:26
股市必读:百克生物(688276)4月23日披露最新机构调研信息
股市必读:百克生物年报 - 第四季度单季净利润同比下降749.87%
证券之星 · 04-23 03:37
股市必读:百克生物年报 - 第四季度单季净利润同比下降749.87%
图解百克生物一季报:第一季度单季净利润同比下降426.43%
证券之星 · 04-22
图解百克生物一季报:第一季度单季净利润同比下降426.43%
百克生物:公司水痘减毒活疫苗为国内首个去除明胶保护剂、有效期长达36个月的水痘疫苗产品
每日经济新闻 · 04-03
百克生物:公司水痘减毒活疫苗为国内首个去除明胶保护剂、有效期长达36个月的水痘疫苗产品
3月23日百克生物跌5.74%,金鹰鑫瑞混合A基金重仓该股
证券之星 · 03-23
3月23日百克生物跌5.74%,金鹰鑫瑞混合A基金重仓该股
蛇串疮百亿级市场的“冰与火”:GSK全球市场“独舞” 百克生物遭遇“极寒”
华夏时报网 · 03-21
蛇串疮百亿级市场的“冰与火”:GSK全球市场“独舞” 百克生物遭遇“极寒”
百克生物2025年营收下滑51.85%,明星产品遭遇大规模退货
蓝鲸财经 · 03-03
百克生物2025年营收下滑51.85%,明星产品遭遇大规模退货
每周股票复盘:百克生物(688276)2025年净亏2.72亿
证券之星 · 03-01
每周股票复盘:百克生物(688276)2025年净亏2.72亿
百克生物上市以来首亏 产品价格腰斩 股价跌剩零头
市场资讯 · 02-28
百克生物上市以来首亏 产品价格腰斩 股价跌剩零头
百克生物(688276)披露2025年度业绩快报,2月26日股价下跌0.6%
证券之星 · 02-26
百克生物(688276)披露2025年度业绩快报,2月26日股价下跌0.6%
百克生物(688276.SH)2025年度归母净亏损2.72亿元
智通财经 · 02-26
百克生物(688276.SH)2025年度归母净亏损2.72亿元
每周股票复盘:百克生物(688276)预计2025年净利亏损2.2亿至2.8亿元
证券之星 · 01-18
每周股票复盘:百克生物(688276)预计2025年净利亏损2.2亿至2.8亿元
百克生物(688276.SH)发预亏,预计2025年度归母净亏损2.2亿元到2.8亿元
智通财经 · 01-16
百克生物(688276.SH)发预亏,预计2025年度归母净亏损2.2亿元到2.8亿元
百克生物(688276)披露2025年年度业绩预亏公告,1月16日股价下跌0.3%
证券之星 · 01-16
百克生物(688276)披露2025年年度业绩预亏公告,1月16日股价下跌0.3%
流感疫情持续,防控系统工程再受考验
证券之星 · 2025-12-31
流感疫情持续,防控系统工程再受考验
每周股票复盘:百克生物(688276)更换持续督导保荐代表人
证券之星 · 2025-12-28
每周股票复盘:百克生物(688276)更换持续督导保荐代表人
百克生物:公司构建了以“升级换代、填补空白、创新突破”为方向的梯队式研发策略
证券日报 · 2025-12-12
百克生物:公司构建了以“升级换代、填补空白、创新突破”为方向的梯队式研发策略
生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?
投资时报 · 2025-11-24
生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?
加载更多
公司概况
公司名称:
长春百克生物科技股份公司
所属行业:
医药制造业
上市日期:
2021-06-25
主营业务:
长春百克生物科技股份公司的主营业务是传染病防治的创新生物药的研发、生产及销售。公司的主要产品是水痘疫苗、流感疫苗、带状疱疹疫苗。自设立以来,公司被国家发展和改革委员会认定为“国家级企业技术中心”、被吉林省科技厅认定为高新技术企业,批准设立“吉林省疫苗科技创新中心”、被吉林省发改委批准设立“吉林省疫苗工程研究中心”、被长春国家生物产业基地认定为“长春国家生物产业基地疫苗工程研究中心”、被人力资源和社会保障部、全国博士后管委会认定为“博士后科研工作站”。
发行价格:
36.35
{"stockData":{"symbol":"688276","market":"SH","secType":"STK","nameCN":"百克生物","latestPrice":17.87,"timestamp":1777014000000,"preClose":17.73,"halted":0,"volume":1830252,"delay":0,"changeRate":0.0079,"floatShares":413999999,"shares":413999999,"eps":-0.6458,"marketStatus":"已收盘","change":0.14,"latestTime":"04-24 15:00:00","open":17.68,"high":17.93,"low":17.56,"amount":32489900,"amplitude":0.0209,"askPrice":17.89,"askSize":113,"bidPrice":17.87,"bidSize":440,"shortable":0,"etf":0,"ttmEps":-0.6458,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":17.73,"symbolType":"stock_kcb","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":19.5,"lowLimit":15.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":413657598,"isCdr":false,"pbRate":1.92,"roa":"--","roe":"--","epsLYR":-0.64,"committee":0.379121,"marketValue":7392000000,"turnoverRate":0.0044,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-04-27。","afterMarket":{"amount":0,"volume":0,"close":17.87,"buyVolume":0,"sellVolume":0,"time":1777016037559,"indexStatus":"已收盘 04-24 15:30:00","preClose":17.73},"floatMarketCap":7392000000},"requestUrl":"/m/hq/s/688276","defaultTab":"news","newsList":[{"id":"2629138815","title":"百克生物寒冬已至:营收降五成、净利暴跌213% 核心产品量价齐跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2629138815","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629138815?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:00","pubTimestamp":1777017600,"startTime":"0","endTime":"0","summary":" 近日,百克生物披露2025年年度报告。数据显示,公司全年营业总收入6.05亿元,同比下滑50.77%,营收规模近乎腰斩;归母净利润-2.63亿元,同比暴跌213.14%,扣非净利润-2.79亿元,同比降幅达221.56%,首次出现年度亏损。 季度数据显示,公司盈利从一季度微利106.43万元,逐步演变为二季度亏7463.77万元、三季度亏8467.71万元、四季度亏1.04亿元,经营困境呈逐季加深态势,尚未见到企稳复苏信号。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-04-24/doc-inhvqwee3153530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629862552","title":"【私募调研记录】瞰道资产调研百克生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2629862552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629862552?lang=zh_cn&edition=full","pubTime":"2026-04-24 08:02","pubTimestamp":1776988945,"startTime":"0","endTime":"0","summary":"根据市场公开信息及4月23日披露的机构调研信息,知名私募瞰道资产近期对1家上市公司进行了调研,相关名单如下:1)百克生物 调研纪要:公司2025年营业收入60,507.29万元,净亏损26,258.07万元;2026年Q1营收14,735.14万元,净利润-347.41万元。业绩下滑主因带状疱疹疫苗收入下降及退货、水痘疫苗销量减少。公司主动下调带状疱疹疫苗价格,提升可及性,渠道库存处于合理水平。mRNA疫苗方面,HSV-2疫苗进入Ⅰ期临床,投资传信生物推进肿瘤mRNA疫苗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026042400023285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629863969","title":"股市必读:百克生物(688276)4月23日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2629863969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629863969?lang=zh_cn&edition=full","pubTime":"2026-04-24 04:26","pubTimestamp":1776975975,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘,百克生物报收于17.73元,下跌2.37%,换手率0.69%,成交量2.85万手,成交额5043.27万元。来自机构调研要点:公司带状疱疹疫苗因行业竞争加剧、公众接种意愿波动及价格调整等因素导致销售收入下降,部分疫苗因到期未接种发生退货。截至目前,公司在研产品HSV-2疫苗正在开展Ι期临床试验,是国内首个开展临床研究的HSV-2疫苗。传信生物研发的通用型肿瘤mRN疫苗正在开展IIT临床试验,截至2025年12月份已完成10例患者入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400013677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629022719","title":"股市必读:百克生物年报 - 第四季度单季净利润同比下降749.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629022719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629022719?lang=zh_cn&edition=full","pubTime":"2026-04-23 03:37","pubTimestamp":1776886643,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日百克生物披露,截至2026年3月31日公司股东户数为1.17万户,较12月31日减少70.0户,减幅为0.59%。经营活动产生的现金流量净额为231,207,058.17元,同比下降43.12%。长春百克生物科技股份公司关于2025年度拟不进行利润分配的公告长春百克生物科技股份公司2025年度实现归属于母公司所有者的净利润为-262,580,724.19元,母公司累计未分配利润为1,174,443,483.43元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300007994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629059728","title":"图解百克生物一季报:第一季度单季净利润同比下降426.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629059728","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629059728?lang=zh_cn&edition=full","pubTime":"2026-04-22 01:24","pubTimestamp":1776792285,"startTime":"0","endTime":"0","summary":"证券之星消息,百克生物2026年一季报显示,一季度公司主营收入1.47亿元,同比下降9.21%;归母净利润-347.41万元,同比下降426.43%;扣非净利润-500.74万元,同比下降46.76%;负债率25.01%,投资收益-1022.01万元,财务费用59.57万元,毛利率80.95%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200003522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624652634","title":"百克生物:公司水痘减毒活疫苗为国内首个去除明胶保护剂、有效期长达36个月的水痘疫苗产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652634","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624652634?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:25","pubTimestamp":1775211900,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:公司水痘疫苗相比其他公司产品有什么优势?百克生物(688276.SH)4月3日在投资者互动平台表示,公司水痘减毒活疫苗为国内首个去除明胶保护剂、有效期长达36个月的水痘疫苗产品,具有产品滴度高、安全性高以及稳定性好等特点。2026年,公司将深化知识科普教育,通过精准的信息传递,提升水痘疫苗的公众认知度,增强品牌的市场影响力,提升企业的核心竞争力。(文章来源:每日经济新闻)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-03/doc-inhtfkwz8845299.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-03/doc-inhtfkwz8845299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159646","BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621750017","title":"3月23日百克生物跌5.74%,金鹰鑫瑞混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621750017","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621750017?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:37","pubTimestamp":1774255048,"startTime":"0","endTime":"0","summary":"证券之星消息,3月23日百克生物跌5.74%创60日新低,收盘报17.25元,换手率0.78%,成交量3.23万手,成交额5684.96万元。重仓百克生物的公募基金请见下表:根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为金鹰基金的金鹰鑫瑞混合A。金鹰鑫瑞混合A目前规模为0.54亿元,最新净值1.3246,较上一交易日下跌0.23%,近一年上涨2.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621520765","title":"蛇串疮百亿级市场的“冰与火”:GSK全球市场“独舞” 百克生物遭遇“极寒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2621520765","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621520765?lang=zh_cn&edition=full","pubTime":"2026-03-21 10:20","pubTimestamp":1774059600,"startTime":"0","endTime":"0","summary":"春寒料峭谨防“会呼吸的痛”。随着春季气温波动,病毒进入活跃期,流行病传染病高发。带状疱疹,这个民间俗称“蛇串疮”的疾病,正以极高发病率威胁着大众健康。2025年发布的《中国带状疱疹疾病负担与经济学评价研究》显示,带状疱疹新发病例呈现年轻化,全人群终身发病风险超过30%。而与庞大市场需求形成鲜明对比的是,国内疫苗接种率的持续低迷。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603213679560322.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603213679560322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","GSKH","GSK","688276","BK4007","BK4532","BK0239","GSK.UK","BK4585","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616343252","title":"百克生物2025年营收下滑51.85%,明星产品遭遇大规模退货","url":"https://stock-news.laohu8.com/highlight/detail?id=2616343252","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616343252?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:56","pubTimestamp":1772531782,"startTime":"0","endTime":"0","summary":"2023年6月,百克生物的带状疱疹减毒活疫苗感维正式上市。2025年前三季度,该疫苗全球销量同比增长13%。葛兰素史克刚与智飞生物签订协议时,根据2023年公告披露,双方约定了2024年至2026年协议产品及每年度预计的最低年度采购金额,其中2024年带状疱疹疫苗34.4亿元,2025年68.8亿元,2026年103.2亿元。百克生物当年收入中只有带状疱疹疫苗业务有所下滑:2024年,百克生物带状疱疹减毒活疫苗的营业收入降至2.5亿元,同比下降71.54%,直接拖累了整体业绩。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1772531669304336151","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616384306","title":"每周股票复盘:百克生物(688276)2025年净亏2.72亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616384306","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616384306?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:28","pubTimestamp":1772303293,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,百克生物报收于19.63元,较上周的19.52元上涨0.56%。本周,百克生物2月26日盘中最高价报19.99元。本周关注点来自业绩披露要点:百克生物2025年归属净利润亏损2.721亿元,同比由盈转亏。来自公司公告汇总:营业总收入同比下降51.85%,主因带状疱疹疫苗退货及水痘疫苗销量下滑。主要原因为带状疱疹疫苗收入确认后因未接种导致退货、疫苗单价下调以及水痘疫苗销量下滑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614897821","title":"百克生物上市以来首亏 产品价格腰斩 股价跌剩零头","url":"https://stock-news.laohu8.com/highlight/detail?id=2614897821","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614897821?lang=zh_cn&edition=full","pubTime":"2026-02-28 11:52","pubTimestamp":1772250720,"startTime":"0","endTime":"0","summary":" 在2024年净利润腰斩后,疫苗巨头百克生物又曝出了上市以来首次年度亏损。公司最新发布的业绩快报显示,去年公司实现营业总收入5.92亿元,同比大降51.85%;归母净利润亏损2.72亿元,扣非净利润亏损2.89亿元,这也是公司自2021年上市以来首次年度亏损。 由于最近两年业绩不佳,百克生物股价已连跌三年,其中2024年和2025年该股分别大跌54%和24%,目前股价仅相当于历史高点的一成多,跌幅可谓惨烈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-28/doc-inhpiwhh9304474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614025659","title":"百克生物(688276)披露2025年度业绩快报,2月26日股价下跌0.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614025659","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614025659?lang=zh_cn&edition=full","pubTime":"2026-02-26 23:09","pubTimestamp":1772118553,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘,百克生物报收于19.73元,较前一交易日下跌0.6%,最新总市值为81.61亿元。该股当日开盘19.9元,最高19.99元,最低19.71元,成交额达3387.1万元,换手率为0.41%。近日,长春百克生物科技股份公司发布2025年度业绩快报。公告指出,主要原因为带状疱疹疫苗收入确认后因未接种导致退货、疫苗单价下调以及水痘疫苗销量下滑。上述数据为初步核算结果,未经审计,最终财务数据以公司正式披露的2025年年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614501308","title":"百克生物(688276.SH)2025年度归母净亏损2.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614501308","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614501308?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:43","pubTimestamp":1772095401,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百克生物 发布2025年度业绩快报,报告期内,公司营业总收入5.92亿元,同比下降51.85%;归属于母公司所有者的净利润-2.72亿元,上年同期23,209.38万元,同比下降217.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604925499","title":"每周股票复盘:百克生物(688276)预计2025年净利亏损2.2亿至2.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925499","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925499?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:15","pubTimestamp":1768680909,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,百克生物报收于20.14元,较上周的20.31元下跌0.84%。本周,百克生物1月13日盘中最高价报20.9元。百克生物预计2025年全年扣非后净利润亏损2.4亿元至3亿元。公司公告汇总长春百克生物科技股份公司预计2025年年度归属于母公司所有者的净利润为-22,000.00万元到-28,000.00万元,同比减少194.79%到220.64%,主要因带状疱疹疫苗销售收入下降、价格调整及水痘疫苗销量减少所致。同时,公司对存货计提减值准备,并因参股公司增资确认投资损失。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603964706","title":"百克生物(688276.SH)发预亏,预计2025年度归母净亏损2.2亿元到2.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603964706","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603964706?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:11","pubTimestamp":1768558266,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百克生物(688276.SH)发布公告,公司预计2025年年度实现归属于母公司所有者的净利润亏损2.2亿元到2.8亿元,与上年同期相比,将出现亏损,减少4.52亿元到5.12亿元,同比减少194.79%到220.64%。报告期内,受行业竞争加剧、民众接种意愿不足、新生儿出生率下降等多重因素影响,公司经营环境面临阶段性挑战,2025年度净利润亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"百克生物(688276.SH)发预亏,预计2025年度归母净亏损2.2亿元到2.8亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603961992","title":"百克生物(688276)披露2025年年度业绩预亏公告,1月16日股价下跌0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603961992","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603961992?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:34","pubTimestamp":1768556088,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,百克生物报收于20.14元,较前一交易日下跌0.3%,最新总市值为83.31亿元。该股当日开盘20.3元,最高20.32元,最低19.98元,成交额达6109.21万元,换手率为0.73%。近日,长春百克生物科技股份公司发布2025年年度业绩预亏公告。公告显示,公司预计2025年年度归属于母公司所有者的净利润为-22,000.00万元到-28,000.00万元,同比减少194.79%到220.64%。此外,公司对存货计提了减值准备,并因参股公司增资确认了投资损失。上年同期归属于母公司所有者的净利润为23,209.38万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600028809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595127727","title":"流感疫情持续,防控系统工程再受考验","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595127727?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:18","pubTimestamp":1767172695,"startTime":"0","endTime":"0","summary":"2025年末,全国流感疫情持续处于高流行水平。产业链协同响应,构建多层次供应保障流感防控是一项系统工程,需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫情中,上市药企正通过全产业链布局,搭建从源头预防到终端治疗的健康保障网络。中成药在本轮疫情中表现活跃。公司表示,金振口服液四季度市场需求回暖,正加紧排产满足市场需要。随着该产品儿童流感新适应症的获批,其在儿科领域的应用场景进一步拓宽。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025123100030908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0074","BK0175","BK0012","SG9999001069.SGD","BK0183","600557","BK0196","300244","002317","BK0197","BK0077","BK0114","603882","600079","BK0070","BK0010","000623","BK0042","BK0060","000999","BK0097","BK0236","BK0146","BK0201","BK0096","BK0164","BK0086","BK0186","BK0046","688276","BK0028","BK0188","603858","BK0187","000756","002603","BK0185","600566","BK0284","BK0250","002393","300937","BK0239","301207","002728"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594242228","title":"每周股票复盘:百克生物(688276)更换持续督导保荐代表人","url":"https://stock-news.laohu8.com/highlight/detail?id=2594242228","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594242228?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:21","pubTimestamp":1766866868,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,百克生物报收于19.19元,较上周的19.31元下跌0.62%。本周,百克生物12月26日盘中最高价报19.36元。本周关注点公司公告汇总:百克生物更换持续督导保荐代表人,范新亮接替朱绍辉。公司首次公开发行股票的持续督导期已于2024年12月31日届满,但因募集资金尚未使用完毕,保荐机构将继续履行相关持续督导义务至募集资金使用完毕为止。公司董事会对朱绍辉先生的贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590950764","title":"百克生物:公司构建了以“升级换代、填补空白、创新突破”为方向的梯队式研发策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2590950764","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590950764?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:06","pubTimestamp":1765548360,"startTime":"0","endTime":"0","summary":"为了保障公司研发战略的稳步推进,支撑研发管线的持续迭代,百克生物建立了“生产一代、研发一代、储备一代”的稳健发展模式。构建了覆盖儿童疫苗、成人疫苗、多联多价疫苗、治疗性疫苗及单克隆抗体的多元化研发管线。2025年百克生物研发成果不断,公司重点研发陆续取得重要里程碑进展。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-12/doc-inhaqhvc7070535.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-12/doc-inhaqhvc7070535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688276","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585540594","title":"生长激素难助业绩长高!昔日“东北药茅”欲借港股翻盘?","url":"https://stock-news.laohu8.com/highlight/detail?id=2585540594","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585540594?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:21","pubTimestamp":1763972460,"startTime":"0","endTime":"0","summary":"编者按:拆解企业招股、估值、上市表现,以专业视角记录资本脉动。投资时间网携手标点财经联袂锻造“解码港股IPO”特别策划,深度探寻每一次资本浪潮背后的机遇与逻辑,敬请关注。投资时间 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251124/c672688967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0028","BK0188","BK0239","BK0075","BK0057","000661","BK0046","688276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777140988590,"stockEarnings":[{"period":"1week","weight":0.0142},{"period":"1month","weight":0.0096},{"period":"3month","weight":-0.1329},{"period":"6month","weight":-0.1888},{"period":"1year","weight":-0.123},{"period":"ytd","weight":-0.0525}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春百克生物科技股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11710人(较上一季度减少0.59%)","perCapita":"35325股","listingDate":"2021-06-25","address":"吉林省长春市朝阳区高新开发区火炬路1260号","registeredCapital":"41365万元","survey":" 长春百克生物科技股份公司的主营业务是传染病防治的创新生物药的研发、生产及销售。公司的主要产品是水痘疫苗、流感疫苗、带状疱疹疫苗。自设立以来,公司被国家发展和改革委员会认定为“国家级企业技术中心”、被吉林省科技厅认定为高新技术企业,批准设立“吉林省疫苗科技创新中心”、被吉林省发改委批准设立“吉林省疫苗工程研究中心”、被长春国家生物产业基地认定为“长春国家生物产业基地疫苗工程研究中心”、被人力资源和社会保障部、全国博士后管委会认定为“博士后科研工作站”。","listedPrice":36.35},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百克生物,688276,百克生物股票,百克生物股票老虎,百克生物股票老虎国际,百克生物行情,百克生物股票行情,百克生物股价,百克生物股市,百克生物股票价格,百克生物股票交易,百克生物股票购买,百克生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百克生物(688276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百克生物(688276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}